Amerikanische Gesellschaft für Hirudotherapie

Thrombin induced tumour growth - pharmacological control

Research article published in Hamostaseologie (2007)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportArzneimittelentwicklungSpeichel-PharmakologieNowak G et al. · Hamostaseologie, 2007

Abstract

The central enzyme of blood coagulation, the serine proteinase thrombin, is capable to modify the growth of tumour cells by interaction with protease activated receptors 1 and 4 of the tumour cells. Thrombin is permanently available in tumour micro environment; meizothrombin is generated from prothrombin at a tumour specific activation complex and can influence tumour cell growth via PAR-1 and 7-transdomain protein receptor signalling pathway, too. PEG-coupled direct thrombin inhibitors that possess special pharmacokinetic characteristics and that have been designed for long lasting efficacy in extracellular space, control serine proteinase activity in tumour micro environment and therefore they own a high potential anti-tumour efficacy. In xenographic tumour models this new substance class has shown a significant carcinostatic effect.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeEnglish AbstractJournal Article
Indexed MeSH termsAmino Acid SequenceCell DivisionHirudinsHumansModels, MolecularMolecular Sequence DataNeoplasmsProtein ConformationReceptor, PAR-1Receptors, ThrombinSignal TransductionThrombin

Zusammenfassung

The central enzyme of blood coagulation, the serine proteinase thrombin, is capable to modify the growth of tumour cells by interaction with protease activated receptors 1 and 4 of the tumour cells.

Warum dies für die Hirudotherapie relevant ist

This abstract examines how thrombin modifies tumor cell growth through protease-activated receptors (PAR-1 and PAR-4) and tests PEG-coupled direct thrombin inhibitors as a means of controlling thrombin activity in the tumor microenvironment, reporting significant carcinostatic effects in xenographic tumor models. This work is tangentially relevant to the broader pharmacology of thrombin inhibition. However, the abstract makes no mention of hirudin, leeches, or any leech-derived compounds. The study involves a PEG-coupled inhibitor class, not hirudin or related molecules, so the connection to hirudotherapy or the leech secretome is not established by this abstract.

Zitation

Thrombin induced tumour growth - pharmacological control

Nowak G et al. · Hamostaseologie, 2007

DOIPubMed

Verwandter klinischer Kontext

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

Drug PipelineDrug DevelopmentDirect Thrombin InhibitorsSalivary Gland SecretionAnti-Inflammatory MechanismsSalivary ComplexHemostasisHirudinOtolaryngology

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.